The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers
Open Access
- 1 July 2006
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines
- Vol. 2 (4) , 167-173
- https://doi.org/10.4161/hv.2.4.2944
Abstract
Background: The live attenuated DEN1 vaccine candidate virus rDEN1Δ30 has been evaluated in preclinical animal models and found to be attenuated and immunogenic. These promising preclinical studies have identified rDEN1Δ30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial. Methods: rDEN1Δ30 at a dose of 103 pfu was administered as a single inoculation to twenty healthy adult volunteers. Eight additional volunteers received placebo. Volunteers were monitored closely for adverse events and serum was collected on study days 0, 28, 42, and 180 for determination of neutralizing antibody titer. Results: The vaccine was well tolerated by the vaccinees. The most common adverse events observed were a transient asymptomatic rash in 40% of vaccinees and a mild neutropenia in 45% of vaccinees. No vaccinee developed a dengue-like illness. The vaccine was highly infectious and immunogenic with 95% of vaccinees developing a ? 4-fold rise in serum neutralizing antib...Keywords
This publication has 0 references indexed in Scilit: